Brief: Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology
04/03/2026 21:28
March 4 (Reuters) - PepGen Inc PEPG.O: PEPGEN INC: U.S. FDA PLACES FREEDOM2 TRIAL ON PARTIAL CLINICAL HOLD RELATED TO PRECLINICAL PHARMACOLOGY AND TOXICOLOGY PEPGEN INC: REITERATES GUIDANCE FOR REPORTING DATA FROM FREEDOM2 5 MG/KG COHORT IN Q1 2026 AND FROM 10 MG/KG COHORT IN 2H 2026 PEPGEN INC - RECEIVES REGULATORY CLEARANCE TO INITIATE FREEDOM2 IN SOUTH KOREA, AUSTRALIA, AND NEW ZEALAND Source text: ID:nBwbh3kDba Further company coverage: PEPG.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PepGen
See all newsDyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview